🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07553442
Recruiting Phase 2

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

NCT07553442 · tracked via the Priya Life Science USA tracker
Sponsor
Alnylam Pharmaceuticals
Phase
Phase 2
Started
2026-04-27
Last updated
2026-09-14

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

ALN-AGT01 RVRPlaceboZilebesiran

ALN-AGT01 RVR: ALN-AGT01 RVR will be administered subcutaneously (SC)

Placebo: Placebo will be administered SC

Zilebesiran: Zilebesiran will be administered SC

Study summary

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Part A: Inclusion Criteria * Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg * Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications Part B: Inclusion Criteria * Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg * Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks Both Parts: Exclusion Criteria * Has known secondary hypertension or serum potassium more than 5 mmol/L * Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2 Note: other protocol defined inclusion / exclusion criteria apply

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Clinical Trial Site Lake Forest California Recruiting
Clinical Trial Site Tampa Florida Active Not Recruiting
Clinical Trial Site Savannah Georgia Active Not Recruiting

More Alnylam Pharmaceuticals trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07553442 on ClinicalTrials.gov ↗ ← All trials in the USA